{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+regimen", "query": { "intervention": "EPOCH regimen" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 674, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+regimen&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-07T13:11:25.939Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00267748", "title": "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Sunitinib Malate Continuous Daily Dosing", "type": "DRUG" }, { "name": "Sunitinib Malate Schedule 4/2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2005-12", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-09-05", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 156, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 114 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00267748" }, { "nct_id": "NCT00948649", "title": "Effects of Chantix on Relapse Prevention for Smoking Cessation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Nicotine Dependence" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Varenicline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 62, "start_date": "2006-09", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2010-08-17", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00948649" }, { "nct_id": "NCT04540380", "title": "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Failure" ], "interventions": [ { "name": "Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab", "type": "DRUG" }, { "name": "Combined bone marrow and kidney transplant", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2021-09-01", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04540380" }, { "nct_id": "NCT03509350", "title": "Vitamin C, Thiamine, and Steroids in Sepsis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Vitamin C", "type": "DRUG" }, { "name": "Thiamine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Vitamin C Placebo", "type": "DRUG" }, { "name": "Thiamine Placebo", "type": "DRUG" }, { "name": "Hydrocortisone Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2018-08-22", "completion_date": "2020-01-29", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 43, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03509350" }, { "nct_id": "NCT04877288", "title": "A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Allograft Recipients" ], "interventions": [ { "name": "Belatacept", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Cyclosporine A", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Enteric Coated Mycophenolate Sodium", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 102, "start_date": "2021-07-21", "completion_date": "2034-06-30", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04877288" }, { "nct_id": "NCT03895203", "title": "A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma SRL", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 852, "start_date": "2019-04-03", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 25, "location_summary": "Phoenix, Arizona • San Diego, California • Tustin, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Palm Harbor", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03895203" }, { "nct_id": "NCT05822752", "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-09-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 20, "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822752" }, { "nct_id": "NCT02142569", "title": "Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Cholesterol Lowering" ], "interventions": [ { "name": "Sugar Pill", "type": "DRUG" }, { "name": "Chinese Red Yeast Rice (CRYR)", "type": "DRUG" }, { "name": "CRYR + TRF", "type": "DRUG" }, { "name": "Tocotrienol-enriched Fraction of Palm Oil (TRF)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "35 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-10-30", "completion_date": "2016-02-09", "has_results": false, "last_update_posted_date": "2019-01-11", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02142569" }, { "nct_id": "NCT00194766", "title": "Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2000-07", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2007-11-14", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00194766" }, { "nct_id": "NCT05768854", "title": "Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Osteogenesis Imperfecta" ], "interventions": [ { "name": "Bisphosphonate", "type": "DRUG" }, { "name": "Setrusumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 69, "start_date": "2023-06-14", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-09-07T13:11:25.939Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768854" } ] }